SNPHF Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 апр. 2024 @ 21:03):

Stats
Объем за сегодня	31.00
Средний объем	42.00
Рыночная капитализация	3.37B
EPS	$24.13 ( 2023-11-06 )
Last Dividend	$0.121 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	19.29
ATR14	$0 (0.00%)

Santen Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Santen Pharmaceutical Финансовые показатели

Annual	2023
Выручка:	$279.04B
Валовая прибыль:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2023
Выручка:	$279.04B
Валовая прибыль:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2022
Выручка:	$266.26B
Валовая прибыль:	$156.59B (58.81 %)
EPS:	$68.07

FY	2021
Выручка:	$249.61B
Валовая прибыль:	$151.38B (60.65 %)
EPS:	$17.09

Financial Reports:

No articles found.

Santen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.111 (N/A)	$0 (N/A)	$0.121 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Santen Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.85 - Stable (3.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0980	2014-03-27
Last Dividend	$0.121	2023-03-30
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$2.40	--
Avg. Dividend % Per Year	0.00%	--
Score	3.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.85
Div. Directional Score	7.99	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RWCB	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
FIDS	Ex Dividend Junior	2023-05-18	Annually	0.00%
WEGZY	Ex Dividend Knight	2023-09-29	Bi-Monthly	0.00%
MAORF	Ex Dividend Junior	2023-08-17	Sporadic	0.00%
CLZNY	Ex Dividend Knight	2023-06-09	Annually	0.00%
SNMCY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
HCBC	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
AMFC	Ex Dividend Knight	2023-08-31	Annually	0.00%
NHYDY	Ex Dividend Knight	2023-05-11	Annually	0.00%
CSXXY	Ex Dividend Knight	2023-09-15	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0918	1.500	8.16	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0648	1.200	7.84	9.41	[0 - 0.3]
returnOnEquityTTM	0.0924	1.500	-0.0848	-0.127	[0.1 - 1]
payoutRatioTTM	0.429	-1.000	5.71	-5.71	[0 - 1]
currentRatioTTM	2.46	0.800	2.72	2.17	[1 - 3]
quickRatioTTM	1.841	0.800	3.88	3.10	[0.8 - 2.5]
cashRatioTTM	0.897	1.500	6.13	9.19	[0.2 - 2]
debtRatioTTM	0.0786	-1.500	8.69	-10.00	[0 - 0.6]
interestCoverageTTM	20.13	1.000	3.66	3.66	[3 - 30]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.113	-1.500	9.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.606	1.000	3.24	3.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.143	1.000	9.14	9.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.706	0.800	8.63	6.90	[0.5 - 2]
Total Score				11.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.69	1.000	8.21	0	[1 - 100]
returnOnEquityTTM	0.0924	2.50	-0.0545	-0.127	[0.1 - 1.5]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0150	1.500	9.63	0	[0 - 0.4]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.429	1.500	5.71	-5.71	[0 - 1]
pegRatioTTM	-0.000754	1.500	-3.34	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.225	1.000	6.86	0	[0.1 - 0.5]
Total Score				4.85

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.